Matt Likens’ two decades-plus at Baxter cultivated in him a desire to deliver “critical therapies for life-threatening conditions.” He found great success as CEO of Ulthera, an aesthetics company using ultrasound energy, but once that company was sold to Merz he sought a way back to developing devices that can help sick people become well. He found such an opportunity at GT Medical Technologies, developer of collagen-based GammaTiles – tiles that deliver postsurgery radiation to prevent the regrowth of tumors in residual cells. In this podcast, Likens details the benefits of GT’s STaRT therapy. This is his second stint as a start-up CEO and Likens shares the successful approaches he’s borrowing from Ulthera including setting a Big Hairy Audacious Goal (BHAG) – “Creating the New Standard of Care for Patients with Brain Tumors.” He also mentions the company’s six operating principles:
- Constructive Engagement
President & CEO
GT Medical Technologies
Mr. Likens is the President and CEO of GT Medical Technologies. He comes to GT having previously led Ulthera from pre-commercial to over $100M in revenue and a $600M exit. His prior experience includes 5 years as President of GMP Wireless Medical and a 23 year career at Baxter,leading business units in both the US and Europe.
Meet Our Host
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.